CLLS has been the subject of a number of other reports. BTIG Research started coverage on Cellectis in a research note on Friday, August 9th. They issued a buy rating and a $37.00 price target for the company. Goldman Sachs Group set a $20.00 price target on Cellectis and gave the company a hold rating in a research note on Monday, August 12th. Citigroup reiterated a neutral rating and issued a $22.00 price target on shares of Cellectis in a research note on Friday, May 24th. Zacks Investment Research cut Cellectis from a hold rating to a sell rating in a research note on Monday, August 12th. Finally, ValuEngine upgraded Cellectis from a sell rating to a hold rating in a research note on Thursday, August 1st. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of Hold and a consensus target price of $31.67.
Shares of CLLS opened at $12.42 on Friday. Cellectis has a 52 week low of $11.70 and a 52 week high of $29.97. The stock has a market capitalization of $532.90 million, a price-to-earnings ratio of -6.44 and a beta of 1.72. The company has a debt-to-equity ratio of 0.11, a quick ratio of 8.46 and a current ratio of 8.47. The stock has a fifty day moving average of $14.67 and a 200-day moving average of $17.08.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Financial Gravity Wealth Inc. acquired a new stake in Cellectis in the first quarter valued at $96,000. Cubist Systematic Strategies LLC acquired a new stake in Cellectis in the second quarter valued at $103,000. Aperio Group LLC acquired a new stake in Cellectis in the second quarter valued at $147,000. A.R.T. Advisors LLC acquired a new stake in Cellectis in the second quarter valued at $171,000. Finally, OneAscent Financial Services LLC acquired a new stake in Cellectis in the second quarter valued at $257,000. Institutional investors and hedge funds own 31.95% of the company’s stock.
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
Recommended Story: How does a security become overbought?
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.